Compare ANEB & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANEB | COCH |
|---|---|---|
| Founded | 2020 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.8M | 24.4M |
| IPO Year | 2021 | N/A |
| Metric | ANEB | COCH |
|---|---|---|
| Price | $2.25 | $0.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 16.6K | ★ 458.6K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $208,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $29.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.80 | $0.64 |
| 52 Week High | $3.42 | $2.25 |
| Indicator | ANEB | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 45.93 | 50.34 |
| Support Level | $2.26 | $0.80 |
| Resistance Level | $2.30 | $0.86 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 41.18 | 59.29 |
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.